Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY24 results · Apr–Jun 2023
Ajanta Pharma reported revenue from operations of ₹1,021.04 crore (up 7.4% from Q1 FY23) and net profit of ₹208.12 crore (up 19.2% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,021.04 | 950.93 | +7.4% | 881.84 | +15.8% |
| Other income | 31.75 | 32.76 | −3.1% | 36.83 | −13.8% |
| Total income | 1,052.79 | 983.69 | +7.0% | 918.67 | +14.6% |
| Profit before tax | 269.04 | 221.86 | +21.3% | 152.05 | +76.9% |
| Net profit for the period | 208.12 | 174.62 | +19.2% | 122.25 | +70.2% |
| EPS, basic (₹) | 16.53 | 13.63 | +21.3% | 9.54 | +73.3% |
| Net margin (%) | 20.4 | 18.4 | 13.9 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,014.58 | 850.29 | +19.3% | 848.86 | +19.5% |
| Other income | 31.46 | 35.42 | −11.2% | 36.75 | −14.4% |
| Total income | 1,046.04 | 885.71 | +18.1% | 885.61 | +18.1% |
| Profit before tax | 275.37 | 190.35 | +44.7% | 147.96 | +86.1% |
| Net profit for the period | 212.04 | 150.37 | +41.0% | 117.21 | +80.9% |
| EPS, basic (₹) | 16.84 | 11.74 | +43.4% | 9.15 | +84.0% |
| Net margin (%) | 20.9 | 17.7 | 13.8 |
Consolidated
- Filed with BSE
- 27 Jul 2023, 19:05 IST
- Board meeting
- 27 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2023, 19:05 IST
- Board meeting
- 27 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE